

1 Table. S4. Preliminary analysis of costs related to the side effect management for irinotecan-  
 2 based combination therapies.

Complication (grade 3-4)	Direct cost of comp. management	Minocycline + Irinotecan (Iri)		Bevacizumab + Irinotecan		Etoposide + Irinotecan	
		Rate of comp. (%) **	Estimated cost from comps.	Rate of comp. (%) ¶	Estimated cost from comps.	Rate of comp. (%) §	Estimated cost from comps.
Neutropenia *	\$7,546	31.4	\$2369.5	11.5	\$867.8	52.4	\$3,954.2
Thrombocytopenia *	\$3,268	1.7	\$55.6	3.8	\$124.2	2.4	\$78.5
Febrile Neutropenia		5.8				7.1	
Cramp/nausea		16.1		3.8		11.9	
Diarrhea	\$1,860	31	\$576.6	3.8	\$70.7	4.8	\$89.3
Vomiting (per cycle)	\$85	12.1	\$10.3	3.8	\$3.3	7.1	\$6.1
<b>Total expected costs from complications</b>			<b>\$3,012</b>		<b>\$1,066</b>		<b>\$4,129</b>

\*Calhoun *et al.* Evaluating the Total Costs of Chemotherapy-Induced Toxicity: Results from a Pilot Study with Ovarian Cancer Patients. *Oncologist*. 2001;6(5):441-5.

\*\*Rate of combination for irinotecan – Source: Camptosar FDA label

¶ Ying Liu *et al.* Low-dose-intensity bevacizumab with weekly irinotecan for platinum- and taxanes-resistant epithelial ovarian cancer. *Cancer Chemother Pharmacol*. 2015; 75(3): 645–651.

§ Shoji T *et al.* Phase II clinical study of the combination chemotherapy regimen of irinotecan plus oral etoposide for the treatment of recurrent ovarian cancer. *Int J Gynecol Cancer*. 2011 Jan;21(1):44-50.